SJS Investment Consulting’s Supernus Pharmaceuticals SUPN Stock Holding History

SJS Investment Consulting’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$187	Hold	4	–	–	﹤0.01%	2489
2026 Q1	$207	Buy	4 +2	+100%	+$102	﹤0.01%	1976
2025 Q4	$100	Hold	2	–	–	﹤0.01%	1945
2025 Q3	$96	Hold	2	–	–	﹤0.01%	1577
2025 Q2	$64	Sell	2 -1	-33%	-$32	﹤0.01%	1504
2025 Q1	$99	Hold	3	–	–	﹤0.01%	1521
2024 Q4	$109	Sell	3 -1	-25%	-$35	﹤0.01%	1516
2024 Q3	$125	Hold	4	–	–	﹤0.01%	1557
2024 Q2	$107	Hold	4	–	–	﹤0.01%	1577
2024 Q1	$137	Sell	4 -1	-20%	-$30	﹤0.01%	1544
2023 Q4	$145	Buy	5 +1	+25%	+$27	﹤0.01%	1510
2023 Q3	$111	Hold	4	–	–	﹤0.01%	1536
2023 Q2	$121	Buy	4 +3	+300%	+$105	﹤0.01%	1486
2023 Q1	$37	Buy	+1	New	+$38	﹤0.01%	1540

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

SJS Investment Consulting's SUPN Position: Q2 2026 in Review

SJS Investment Consulting held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 4 shares worth $187. The position accounts for ﹤0.01% of the portfolio, ranked #2489.

SJS Investment Consulting first reported a position in SUPN in Q1 2023 and has held it in 14 quarters since. The position peaked at $207 in Q1 2026. 131 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

SJS Investment Consulting held 4 shares of Supernus Pharmaceuticals worth $187 as of Q2 2026.
SJS Investment Consulting left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
Supernus Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2489 holding.
SJS Investment Consulting first reported a position in Supernus Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
SJS Investment Consulting's Supernus Pharmaceuticals position peaked at $207 in Q1 2026.
131 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.